OOIR: Observatory of International Research

Papers

(The H4-Index of JCO Precision Oncology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion	90
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B	81
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	76
CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone	75
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine	72
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	71
Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations	69
Identification and Validation of Gastric Adenocarcinoma Prognosis Features Based on Neutrophil-Related Genes	62
Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations	59
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	59
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab	56
Anti-Epidermal Growth Factor Receptor Therapy in EGFR -Amplified Esophagogastric Cancers: An Underestimated Efficacy	55
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma	55
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	54
Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer	52
Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma	51
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types	50
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study	50
Prognostic Role of MTAP Loss in Cholangiocarcinoma	45
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	45
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma	44
Erratum: Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States	42
Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?	40
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer	40
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network	40

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care	40
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	39
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms	37
Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results	36
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer	36
Identification of Targetable EGFR Mutations in Ovarian Cancer	34
Acknowledgment of Reviewers, 2025	34
Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	33